Our single-center retrospective study focused on Stage IV Clear Cell Renal Cell Carcinoma patients who received first-line sunitinib therapy and found that baseline tumor apparent diffusion coefficient value derived from 3T diffusion weighted imaging showed different level in different response group. Baseline tumor ADC value also had significant correlation with progression-free survival. Patients with higher tumor ADC value had significantly longer progression-free survival. Basline tumor ADC can be a potential predictor in assessing targeted therapy response of Stage IV ccRCC.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords